UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike
Executive Summary
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
You may also be interested in...
UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.
Medicines for Europe Calls Out Threat Of Generics Supply Consolidation In EU Market
Off-patent drugs industry trade group Medicines for Europe has penned an open letter to the EU containing several suggestions for how the union might tackle supply chain pressures in the generics sector.